Leerink Partners Maintains Outperform on Hologic, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on Hologic but lowered its price target from $95 to $90.
October 08, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Leerink Partners has maintained an 'Outperform' rating on Hologic but lowered its price target from $95 to $90, indicating a slightly less optimistic outlook.
The 'Outperform' rating suggests continued confidence in Hologic's performance, but the lowered price target indicates a slightly reduced expectation for future gains. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100